Cargando…

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

BACKGROUND: Diabetic men have lowered overall risk of prostate cancer (PCa), but the role of hyperglycaemia is unclear. In this cohort study, we estimated PCa risk among men with diabetic fasting blood glucose level. METHODS: Participants of the Finnish Randomized Study of Screening for Prostate Can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murtola, Teemu J., Vihervuori, Ville JY, Lahtela, Jorma, Talala, Kirsi, Taari, Kimmo, Tammela, Teuvo LJ, Auvinen, Anssi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943324/ https://www.ncbi.nlm.nih.gov/pubmed/29563633 http://dx.doi.org/10.1038/s41416-018-0055-4

Ejemplares similares

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
por: Neupane, Subas, et al.
Publicado: (2021)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Outcomes of prostate cancer screening among men using antidiabetic medication
por: Vettenranta, A., et al.
Publicado: (2021)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
por: Booth, Neill, et al.
Publicado: (2019)

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study
por: Peltomaa, A. I., et al.
Publicado: (2021)

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC
por: Pashayan, Nora, et al.
Publicado: (2015)

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
por: Murtola, T J, et al.
Publicado: (2009)

Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them
por: Siltari, Aino, et al.
Publicado: (2021)

False-positive screening results in the Finnish prostate cancer screening trial
por: Kilpeläinen, T P, et al.
Publicado: (2010)

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
por: Sipeky, Csilla, et al.
Publicado: (2021)

PALB2 variants in hereditary and unselected Finnish Prostate cancer cases
por: Pakkanen, Sanna, et al.
Publicado: (2009)

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
por: Rannikko, Antti, et al.
Publicado: (2022)

Overall and worst gleason scores are equally good predictors of prostate cancer progression
por: Tolonen, Teemu T, et al.
Publicado: (2011)

Missingness in the expanded prostate cancer index short form (EPIC-26) – prevalence, patterns, and explanatory factors
por: Talvitie, Anna-Maija, et al.
Publicado: (2023)

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial
por: Raittinen, Paavo V.H., et al.
Publicado: (2021)

MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families
por: Fischer, Daniel, et al.
Publicado: (2015)

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation
por: Nätkin, Reetta, et al.
Publicado: (2023)

Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study
por: Hietikko, Ronja, et al.
Publicado: (2020)

The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth
por: Murtola, Teemu J., et al.
Publicado: (2012)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

European randomized study of prostate cancer screening: first-year results of the Finnish trial
por: Määttänen, L, et al.
Publicado: (1999)

Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases
por: Sattari, Mina, et al.
Publicado: (2023)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005
por: Köninki, Katri, et al.
Publicado: (2009)

Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis
por: Chen, Li-Sheng, et al.
Publicado: (2014)

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system
por: Eskelinen, Tommi, et al.
Publicado: (2021)

Prostate cancer screening: what can we learn from randomised trials?
por: Auvinen, Anssi
Publicado: (2018)

Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland
por: Tikkinen, Kari A.O., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_q8375at862finflea2gs0p2s1b